Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: Final results of a randomized phase III study (ABCSG-24)

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 366-371

  Steger, G G ^a   Greil, R ^b   Lang, A ^c   Rudas, M ^a   Fitzal, F ^a   Mlineritsch, B ^b   Hartmann, B L ^c   Bartsch, R ^a   Melbinger, E ^d   Hubalek, M ^e   Stoeger, H ^f   Dubsky, P ^a   Ressler, S ^b   Petzer, A L ^g   Singer, C F ^h   Muss, C ^b   Jakesz, R ^a   Gampenrieder, S P ^b   Zielinski, C C ^a   Fesl, C ⁱ   Gnant, M ^a   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c Hospital Feldkirch   (Austria)

^d Department of Radiology   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

^h UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

ⁱ Austrian Breast and Colorectal Cancer Study Group   (Austria)

Author keywords

Capecitabine; Docetaxel; Early breast cancer; Epirubicin; Neoadjuvant treatment

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIRUBICIN; HORMONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; TAXOID;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIARRHEA; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EARLY CANCER; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INFUSION RELATED REACTION; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADOLESCENT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893412437     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt508     Document Type: Article

References (17)

1. Kaufmann M, von Minckwitz G, Mamounas EP et al. Recommendations from an International Consensus Conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012; 19: 1508-1516.
2. Steger GG, Galid A, Gnant M et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol 2007; 25: 2012-2018.
3. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
4. von Minckwitz G, Kümmel S, Vogel P et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-562.
5. Untch M, Möbus V, Kuhn W et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 2009; 27: 2938-2945.
6. Stockler MR, Harvey VJ, Francis PA et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29: 4498-4504.
7. O'Shaughnessy J, Miles D et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
8. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
9. O'Shaughnessy J, Paul D et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Cancer Res 2010; 70(Suppl 2): Abstr S4-p2.
10. Muss HB, Berry DA, Cirrincione CT et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-2065.
11. von Minckwitz G, Rezai M, Loibl S et al. Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28: 2015-2023.
12. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320.
13. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
14. Viani GA, Afonso SL, Stefano EJ et al. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.
15. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-749.
16. Buzdar AU, Valero V, Ibrahim NK et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13: 228-233.
17. Dawood S, Gonzalez-Angulo AM, Peintinger F et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 2007; 110: 1195-1200.